Feasibility of atrial fibrillation detection from a novel wearable armband device

SmartWear body sensors for neurological and neurosurgical patients: A review of current and future technologies

Background/objective

Recent technological advances have allowed for the development of smart wearable devices (SmartWear) which can be used to monitor various aspects of patient healthcare. These devices provide clinicians with continuous biometric data collection for patients in both inpatient and outpatient settings. Although these devices have been widely used in fields such as cardiology and orthopedics, their use in the field of neurosurgery and neurology remains in its infancy.

Methods

A comprehensive literature search for the current and future applications of SmartWear devices in the above conditions was conducted, focusing on outpatient monitoring.

Findings

Through the integration of sensors which measure parameters such as physical activity, hemodynamic variables, and electrical conductivity - these devices have been applied to patient populations such as those at risk for stroke, suffering from epilepsy, with neurodegenerative disease, with spinal cord injury and/or recovering from neurosurgical procedures. Further, these devices are being tested in various clinical trials and there is a demonstrated interest in the development of new technologies.

Conclusion

This review provides an in-depth evaluation of the use of SmartWear in selected neurological diseases and neurosurgical applications. It is clear that these devices have demonstrated efficacy in a variety of neurological and neurosurgical applications, however challenges such as data privacy and management must be addressed.

Artificial intelligence in cardiovascular prevention: new ways will open new doors

Prevention and effective treatment of cardiovascular disease are progressive issues that grow in tandem with the average age of the world population. Over recent decades, the potential role of artificial intelligence in cardiovascular medicine has been increasingly recognized because of the incredible amount of real-world data (RWD) regarding patient health status and healthcare delivery that can be collated from a variety of sources wherein patient information is routinely collected, including patient registries, clinical case reports, reimbursement claims and billing reports, medical devices, and electronic health records. Like any other (health) data, RWD can be analysed in accordance with high-quality research methods, and its analysis can deliver valuable patient-centric insights complementing the information obtained from conventional clinical trials. Artificial intelligence application on RWD has the potential to detect a patient's health trajectory leading to personalized medicine and tailored treatment. This article reviews the benefits of artificial intelligence in cardiovascular prevention and management, focusing on diagnostic and therapeutic improvements without neglecting the limitations of this new scientific approach.

Detection of Atrial Fibrillation in Compressively Sensed Electrocardiogram for Remote Monitoring

The objective of this paper is to develop an optimized system to detect Atrial Fibrillation (AF) in compressively sensed electrocardiogram (ECG) for long-term remote patient monitoring. A three-stage system was developed to 1) reject ECG of poor signal quality, 2) detect AF in compressively sensed ECG, and 3) detect AF in selectively reconstructed ECG. The Long-Term AF Database (LTAFDB), sampled at 128 Hz using a 12-bit ADC with a range of 20 mV, was used to validate the system. The LTAFDB had 83,315 normal and 82,435 AF rhythm 30 s ECG segments. Clean ECG from the LTAFDB was artificially contaminated with motion artifact to achieve −12 to 12 dB Signal-to-Noise Ratio (SNR) in steps of 3 dB. The contaminated ECG was compressively sensed at 50% and 75% compression ratio (CR). The system was evaluated using average precision (AP), the area under the curve (AUC) of the receiver operator characteristic curve, and the F1 score. The system was optimized to maximize the AP and minimize ECG rejection and reconstruction ratios. The optimized system for 50% CR had 0.72 AP, 0.63 AUC, and 0.58 F1 score, 0.38 rejection ratio, and 0.38 reconstruction ratio. The optimized system for 75% CR had 0.72 AP, 0.63 AUC, and 0.59 F1 score, 0.40 rejection ratio, and 0.35 reconstruction ratio. Challenges for long-term AF monitoring are the short battery life of monitors and the high false alarm rate due to artifacts. The proposed system improves the short battery life through compressive sensing while reducing false alarms (high AP) and ECG reconstruction (low reconstruction ratio).

Mobile health technology in atrial fibrillation

INTRODUCTION

Mobile health (mHealth) solutions in atrial fibrillation (AF) are becoming widespread, thanks to everyday life devices such as smartphones. Their use is validated both in monitoring and in screening scenarios. In the published literature, the diagnostic accuracy of mHealth solutions wide differs, and their current clinical use is not well established in principal guidelines.

AREAS COVERED

mHealth solutions have progressively built an AF-detection chain to guide patients from the device's alert signal to the health care practitioners' (HCPs) attention. This review aims to critically evaluate the latest evidence regarding mHealth devices and the future possible patient's uses in everyday life.

EXPERT OPINION

The patients are the first to be informed of the rhythm anomaly, leading to the urgency of increasing the patients' AF self-management. Furthermore, HCPs need to update themselves about mHealth devices use in clinical practice. Nevertheless, these are promising instruments in specific populations, such as post-stroke patients, to promote an early arrhythmia diagnosis in the post-ablation/cardioversion period, allowing checks on the efficacy of the treatment or intervention.